View Clinical Trial (Medical Research Study)
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
| City: |
|
Stanford |
| State: |
|
California |
| Zip Code: |
|
94305 |
| Conditions: |
|
Neuroendocrine Tumors - Brain (Nervous System) Cancers - Colon/Rectal Cancer - Colon Cancer - Hepatobiliary Cancers - Hepatocellular Carcinoma (Hepatoma) - Liver |
| Purpose: |
|
The purpose of this study is to determine whether baseline CT perfusion characteristics
(measurements of blood-flow using CT) of hepatic cancers can predict tumor response to
treatment and whether perfusion CT after treatment can be used as a biomarker for response
to treatment. Treatment may consist of chemotherapy or stereotactic body radiotherapy
(SBRT)or embolization therapy.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:3.1.1 Patients with suspected or biopsy-proven liver masses including
unresectable hepatocellular carcinoma (HCC), unresectable colon cancer metastases to the
liver, and metastatic neuroendocrine tumors to the liver will be eligible for enrollment.
3.1.2 Patients who have undergone prior chemotherapy more than one year prior to the
study are eligible for enrollment.
3.1.4 Patients must be 18 years or older. Patients must not be pregnant and, if of
child-bearing age, must take precautions not to become pregnant.
3.1.5 No life expectancy restrictions.
3.1.6 ECOG and Karnofsky Performance Status will not be employed.
3.1.7 Patients with renal failure are ineligible for this study (Glomerular filtration
rate (GFR) must be > 60)
3.1.8 Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:3.2.1 Patients who have undergone prior chemoembolization of
hepatocellular carcinoma (HCC) are ineligible for enrollment. Patients who have undergone
chemotherapy within one year prior to the study are also ineligible for enrollment.
3.2.2 No restrictions regarding use of other investigational agents.
3.2.3 Patients with severe contrast allergy are ineligible.
3.2.4 Patients who are pregnant or are trying to become pregnant are excluded from this
study.
3.2.5 Patients who are cancer survivors or Human Immunodeficiency Virus (HIV)-positive
will not be excluded.
|
| NCT ID: |
|
NCT01163526 |
| Primary Contact: |
|
Principal Investigator
Aya Kamaya
Stanford University
Lindee Burton
Phone: (650) 725-4712
Email: lburton@stanford.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Stanford, California 94305
United States
Lindee Burton
Phone: 650-725-4712
Email: lburton@stanford.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|